Cargando…

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy

To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV) patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or intravitreal injection of aflibercept alone. Retrospective chart review of patients with PCV in a single tertiary referral cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, I-Hsin, Hsia, Yun, Hsieh, Yi-Ting, Ho, Tzyy-Chang, Lai, Tso-Ting, Yang, Chung-May, Yang, Chang-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505609/
https://www.ncbi.nlm.nih.gov/pubmed/34635762
http://dx.doi.org/10.1038/s41598-021-99634-w
_version_ 1784581570129035264
author Ma, I-Hsin
Hsia, Yun
Hsieh, Yi-Ting
Ho, Tzyy-Chang
Lai, Tso-Ting
Yang, Chung-May
Yang, Chang-Hao
author_facet Ma, I-Hsin
Hsia, Yun
Hsieh, Yi-Ting
Ho, Tzyy-Chang
Lai, Tso-Ting
Yang, Chung-May
Yang, Chang-Hao
author_sort Ma, I-Hsin
collection PubMed
description To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV) patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or intravitreal injection of aflibercept alone. Retrospective chart review of patients with PCV in a single tertiary referral center in Taiwan. Chart review of PCV patients treated with PDT and injection of ranibizumab or injection of aflibercept. A total of 101 eyes of 101 patients (38 females and 63 males) were reviewed. Of those, 48 and 53 eyes received primary/adjunctive PDT along with injections of ranibizumab or intravitreal injections of aflibercept only, respectively. Initial visual acuity (VA) and central subfield choroidal thickness were similar between the two groups (p > 0.05). In addition, changes in VA at 3, 6, and 12 months post treatment were similar. The central retinal thickness decreased with either treatment (p < 0.01); however, this change did not translate into VA performance (p > 0.05). In the subgroup analysis of pachychoroid and non-pachychoroid patients, better initial VA and post-treatment VA at 3 months and 6 months was noted in the latter group of patients treated with anti-vascular endothelial growth factor monotherapy (p < 0.05). Aflibercept monotherapy is comparable with PDT plus ranibizumab in PCV patients with PCV (pachychoroid and non-pachychoroid patients). In addition, better prognosis regarding VA was observed in non-pachychoroid patients treated with aflibercept monotherapy.
format Online
Article
Text
id pubmed-8505609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85056092021-10-13 Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy Ma, I-Hsin Hsia, Yun Hsieh, Yi-Ting Ho, Tzyy-Chang Lai, Tso-Ting Yang, Chung-May Yang, Chang-Hao Sci Rep Article To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV) patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or intravitreal injection of aflibercept alone. Retrospective chart review of patients with PCV in a single tertiary referral center in Taiwan. Chart review of PCV patients treated with PDT and injection of ranibizumab or injection of aflibercept. A total of 101 eyes of 101 patients (38 females and 63 males) were reviewed. Of those, 48 and 53 eyes received primary/adjunctive PDT along with injections of ranibizumab or intravitreal injections of aflibercept only, respectively. Initial visual acuity (VA) and central subfield choroidal thickness were similar between the two groups (p > 0.05). In addition, changes in VA at 3, 6, and 12 months post treatment were similar. The central retinal thickness decreased with either treatment (p < 0.01); however, this change did not translate into VA performance (p > 0.05). In the subgroup analysis of pachychoroid and non-pachychoroid patients, better initial VA and post-treatment VA at 3 months and 6 months was noted in the latter group of patients treated with anti-vascular endothelial growth factor monotherapy (p < 0.05). Aflibercept monotherapy is comparable with PDT plus ranibizumab in PCV patients with PCV (pachychoroid and non-pachychoroid patients). In addition, better prognosis regarding VA was observed in non-pachychoroid patients treated with aflibercept monotherapy. Nature Publishing Group UK 2021-10-11 /pmc/articles/PMC8505609/ /pubmed/34635762 http://dx.doi.org/10.1038/s41598-021-99634-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ma, I-Hsin
Hsia, Yun
Hsieh, Yi-Ting
Ho, Tzyy-Chang
Lai, Tso-Ting
Yang, Chung-May
Yang, Chang-Hao
Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title_full Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title_fullStr Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title_full_unstemmed Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title_short Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
title_sort real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505609/
https://www.ncbi.nlm.nih.gov/pubmed/34635762
http://dx.doi.org/10.1038/s41598-021-99634-w
work_keys_str_mv AT maihsin realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT hsiayun realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT hsiehyiting realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT hotzyychang realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT laitsoting realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT yangchungmay realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy
AT yangchanghao realworldexperienceofthetreatmentoutcomebetweenphotodynamictherapycombinedwithranibizumabandafliberceptmonotherapyinpolypoidalchoroidalvasculopathy